Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) – Pipeline Review, H2 2018’, provides in depth analysis on Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Cardiovascular, Dermatology, Musculoskeletal Disorders and Oncology under development targeting Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)

– The report reviews Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Actelion Pharmaceuticals Ltd

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Celgene Corp

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

LG Chem Ltd

Mitsubishi Tanabe Pharma Corp

Novartis AG

Sanofi

Sun Pharma Advanced Research Company Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Overview

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Companies Involved in Therapeutics Development

Actelion Pharmaceuticals Ltd

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Celgene Corp

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

LG Chem Ltd

Mitsubishi Tanabe Pharma Corp

Novartis AG

Sanofi

Sun Pharma Advanced Research Company Ltd

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Drug Profiles

AKP-11 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amiselimod hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0028 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-4058 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986104 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOS-173717 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBP-307 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenerimod Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-1050 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etrasimod arginine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fingolimod hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-253 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LC-510255 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NIBR-0213 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ozanimod hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ponesimod Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-247799 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCD-044 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

siponimod Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize S1P1 for Multiple Sclerosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize S1P1 for Multiple Sclerosis and Rheumatoid Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-968 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Dormant Products

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Discontinued Products

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Product Development Milestones

Featured News & Press Releases

May 11, 2018: Novartis Announces FDA Approval of Gilenya as the First Disease-modifying Therapy for Pediatric Relapsing Multiple Sclerosis

Apr 24, 2018: New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting

Apr 20, 2018: New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients

Mar 23, 2018: Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

Mar 19, 2018: Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis

Feb 27, 2018: Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis

Jan 22, 2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City

Dec 18, 2017: Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis

Nov 09, 2017: Ozanimod Successful in Clinical Trials for Multiple Sclerosis

Oct 28, 2017: Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a

Oct 28, 2017: Efficacy and Safety Results from Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 7th Joint ECTRIMS ACTRIMS Meeting

Oct 27, 2017: Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

Oct 25, 2017: Novartis confirms leadership in multiple sclerosis with scientific advancements and new data presented at ECTRIMS

Oct 25, 2017: Novartis Presents New Data on Siponimod at ECTRIMS

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Actelion Pharmaceuticals Ltd, H2 2018

Pipeline by Arena Pharmaceuticals Inc, H2 2018

Pipeline by Astellas Pharma Inc, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by Boston Pharmaceuticals Inc, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Celgene Corp, H2 2018

Pipeline by GlaxoSmithKline Plc, H2 2018

Pipeline by Idorsia Pharmaceutical Ltd, H2 2018

Pipeline by LG Chem Ltd, H2 2018

Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by Sanofi, H2 2018

Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports